Condition: Moderately to Severely Active Crohn Disease · Sponsor: Abivax S.A.
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the safety and tolerability of obefazimod compared with placebo in subjects who are enrolled in the Extension Phase.
This description comes directly from the study's public registry record.
Study Director · +33 (0) 1 53 83 09 63 · info@abivax.com
Always discuss trial participation with your own doctor first.
| IMC Gulf Coast Gastroenterology, PC | Fairhope, Alabama, United States | Not Yet Recruiting |
| Scottsdale Gastroenterology Specialists | Scottsdale, Arizona, United States | Not Yet Recruiting |
| GI Alliance -Gurnee | Sun City, Arizona, United States | Recruiting |
| Hoag Hospital | Irvine, California, United States | Not Yet Recruiting |
| United Medical Doctors | Murrieta, California, United States | Recruiting |
| Peak Gastroenterology Associates | Colorado Springs, Colorado, United States | Recruiting |
| Clinical Research Of Brandon, LLC | Brandon, Florida, United States | Recruiting |
| West Central Gastroenterology d/b/a Gastro Florida | Clearwater, Florida, United States | Recruiting |
| Auzmer Research | Lakeland, Florida, United States | Recruiting |
| Research Associates of South Florida, LLC | Miami, Florida, United States | Recruiting |
| Wellness Clinical Research | Miami Lakes, Florida, United States | Not Yet Recruiting |
| Advanced Research Institute, Inc. | New Port Richey, Florida, United States | Recruiting |
+ 137 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06456593